<DOC>
	<DOCNO>NCT01579994</DOCNO>
	<brief_summary>About 18 patient take part phase 1 portion trial . In begin study , 3 patient treat low dose ganetespib ( STA-9090 ) standard dose crizotinib . If dose cause significant side effect , increase new patient take part study . The study open Memorial Sloan Kettering Cancer Center .</brief_summary>
	<brief_title>Crizotinib Ganetespib ( STA-9090 ) ALK Positive Lung Cancers</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Histologically cytologically proven diagnosis confirm MSKCC advance lung adenocarcinoma locally advanced metastatic ( stage III/IV ) . Positive translocation inversion event involve ALK gene locus determine standard method ( include limit FISH IHC test ) . No prior treatment crizotinib , may receive prior cytotoxic chemotherapy . Age ≥ 18 year . Measurable ( RECIST 1.1 ) indicator lesion previously irradiate . Karnofsky Performance Status ≥ 70 % Able take oral medication A negative serum pregnancy test obtain within two week prior administration experimental agent premenopausal woman ( last menstrual period ≤ 24 month ago ) . All woman child bear potential ( WOCBP ) sexually active men must agree use adequate method birth control throughout study include use oral contraceptive additional barrier method , double barrier method ( diaphragm spermicidal gel condom contraceptive foam ) , DepoProvera , partner vasectomy and/or tubal libation total abstinence . Prior crizotinib therapy Inadequate recovery toxicity relate prior treatment ( Grade 1 baseline ) . Inadequate hematologic function define : Absolute neutrophil count ( ANC ) &lt; 1,000 cells/mm³ . Platelet count &lt; 75,000/mm³ Hemoglobin &lt; 9.0g/dL . Inadequate hepatic function define : AST and/or ALT &gt; 3x upper limit normal ( ULN ) . Total bilirubin &gt; 2x ULN . Alkaline phosphatase &gt; 3x ULN . Patients hepatic metastasis may ALT/AST ≤ 5x ULN . Patients hepatic and/or bone metastasis may AP ≤ 5x ULN . Inadequate renal function define serum creatinine &gt; 2x ULN Uncontrolled systemic fungal , bacterial , viral infection ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antiinfective medication treatment ) . Patients clinically active brain metastasis ( require therapy steroid radiation therapy ) . Patients clinically stable brain metastasis ( previously treat untreated ) two week eligible . Significant cardiac disease ( e.g . New York Heart Association ( NYHA ) Class 3 4 ; myocardial infarction within past 6 month ; unstable angina ; coronary angioplasty coronary artery bypass graft ( CABG ) within past 6 month ; uncontrolled atrial ventricular cardiac arrhythmia ) . Previously current malignancy sit within last 2 year , exception adequately treat situ carcinoma cervix , basal squamous cell carcinoma skin , prostate cancer require active treatment per National Comprehensive Cancer Network ( NCCN ) guideline . Women pregnant lactating Use drug food know potent CYP3A4 inhibitor ( see Appendix C ) Use drug know potent CYP3A4 inducer ( see Appendix D ) Any condition , opinion Investigator , may compromise safety , compliance patient , would preclude patient successful completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adenocarcinoma</keyword>
	<keyword>Lung</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Crizotinib</keyword>
	<keyword>Ganetespib</keyword>
	<keyword>STA-9090</keyword>
	<keyword>ALK Positive Lung Cancers</keyword>
	<keyword>12-015</keyword>
</DOC>